Simplifying Treatment in Type 2 Diabetes

Type 2 diabetes (T2D) is among the most common reasons to see a general practitioner (GP) and will become more common in the future. The management of T2D is seldom straightforward, and many different factors influence the choice and intensity of therapy, including patient age, comorbidity, resources, life expectancy and the potential for benefits and risks. With this in mind, and the ongoing reporting of the results of cardiovascular outcomes safety trials, it is timely to revisit our knowledge and practices of current antidiabetic agents.

This ALM has been developed to help you improve your knowledge, skills and confidence in choosing the right therapy for adults with T2D, including those with established cardiovascular disease (CVD) and/or chronic kidney disease (CKD).

This ALM will take approximately six (6) hours to complete and has been approved for 40 Accredited CPD points in Royal Australian College of General Practitioners’ (RACGP) Continuing Professional Development (CPD) Program for the 2020-22 triennium. This ALM has been sponsored by Boehringer Ingelheim Pty Ltd and and Eli Lilly Australia Pty Ltd. Accreditation number: 186325